Emerging New Standard of Care for HER2 Breast Cancer

Dr. Stephen Malamud, Mount Sinai
Save to PDF By
Stephen Malamud, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, explains the differences in efficacy for various CDK drugs.

Dr. Malamud describes some significant improvements in progression-free survivalĀ in patients with breast cancer who haveĀ received targeted therapies.


© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy